Sign in Subscribe

msi-h

A collection of 131 issues

Review Examines Immunotherapy in Liver Metastases Beyond MMR Status

Skip to content The CRC Digest ◇ RESEARCH Review Examines Immunotherapy in Liver Metastases Beyond MMR Status A review explored immunotherapy approaches in colorectal cancer liver metastases, examining the hepatic metastatic niche beyond traditional mismatch repair considerations. (Frontiers in Immunology) This content is informational only and does not constitute medical advice.

CRC Research Update — September 21, 2026

Today's colorectal cancer research highlights

Hereditary Syndromes Account for Only 20-25% of Early-Onset Cases

Skip to content The CRC Digest ◇ RESEARCH Hereditary Syndromes Account for Only 20-25% of Early-Onset Cases A comprehensive review reports that hereditary cancer syndromes account for 20-25% of early-onset colorectal cancer cases, with most occurring in the absence of known genetic predispositions. (Oncology Therapy) This content is informational only and

Early-Onset CRC Shows Distinct Molecular Features, Gut Microbiome Implicated

Skip to content The CRC Digest ◇ RESEARCH Early-Onset CRC Shows Distinct Molecular Features, Gut Microbiome Implicated A systematic review finds that most early-onset colorectal cancer cases occur without known genetic predispositions, and emerging evidence points to the gut microbiome as a potential contributor. (Oncology Therapy) This content is informational only

CRC Research Update — September 19, 2026

Today's colorectal cancer research highlights

Gut microbiome may influence resistance to immunotherapy in MSI-H/dMMR colorectal cancer

Skip to content The CRC Digest ◇ RESEARCH Gut microbiome may influence resistance to immunotherapy in MSI-H/dMMR colorectal cancer A narrative review summarizes evidence that the gut microbiome-immune axis regulates antitumor immunity and may mediate both primary and acquired resistance to immune checkpoint inhibitors in MSI-H/dMMR CRC. (Front Cell

CRC Research Update — September 16, 2026

Today's colorectal cancer research highlights

Critical review outlines biomarker-guided treatment selection in metastatic CRC

Skip to content The CRC Digest Critical review outlines biomarker-guided treatment selection in metastatic CRC A structured narrative review separately examines mismatch repair-deficient/MSI-H and microsatellite-stable disease, distinguishing established treatments from investigational strategies based on molecular alterations including BRAF V600E and HER2. (Crit Rev Oncol Hematol) This content is informational

Prospective study examines MSI and CD8+ TILs in neoadjuvant chemotherapy response

Skip to content The CRC Digest Prospective study examines MSI and CD8+ TILs in neoadjuvant chemotherapy response A prospective observational study investigated whether microsatellite instability, CD8+ tumor infiltrating lymphocytes expression, and chemotherapy response are related in colorectal cancer patients receiving neoadjuvant treatment. (Cancer Manag Res) This content is informational only

CRC Research Update — September 13, 2026

Today's colorectal cancer research highlights